MX2017013247A - Infusion arterial hepatica de linfocitos t car. - Google Patents
Infusion arterial hepatica de linfocitos t car.Info
- Publication number
- MX2017013247A MX2017013247A MX2017013247A MX2017013247A MX2017013247A MX 2017013247 A MX2017013247 A MX 2017013247A MX 2017013247 A MX2017013247 A MX 2017013247A MX 2017013247 A MX2017013247 A MX 2017013247A MX 2017013247 A MX2017013247 A MX 2017013247A
- Authority
- MX
- Mexico
- Prior art keywords
- cells
- car
- arterial infusion
- hepatic arterial
- methods include
- Prior art date
Links
- 230000002440 hepatic effect Effects 0.000 title abstract 2
- 238000001802 infusion Methods 0.000 title abstract 2
- 238000000034 method Methods 0.000 abstract 4
- 210000004027 cell Anatomy 0.000 abstract 3
- 102000012406 Carcinoembryonic Antigen Human genes 0.000 abstract 2
- 108010022366 Carcinoembryonic Antigen Proteins 0.000 abstract 2
- 108010019670 Chimeric Antigen Receptors Proteins 0.000 abstract 1
- 108010002350 Interleukin-2 Proteins 0.000 abstract 1
- 206010027457 Metastases to liver Diseases 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 210000001744 T-lymphocyte Anatomy 0.000 abstract 1
- 239000000427 antigen Substances 0.000 abstract 1
- 102000036639 antigens Human genes 0.000 abstract 1
- 108091007433 antigens Proteins 0.000 abstract 1
- 238000011260 co-administration Methods 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 230000001394 metastastic effect Effects 0.000 abstract 1
- 206010061289 metastatic neoplasm Diseases 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 229940124597 therapeutic agent Drugs 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/14—Blood; Artificial blood
- A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/20—Interleukins [IL]
- A61K38/2013—IL-2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/461—Cellular immunotherapy characterised by the cell type used
- A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/463—Cellular immunotherapy characterised by recombinant expression
- A61K39/4631—Chimeric Antigen Receptors [CAR]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/4643—Vertebrate antigens
- A61K39/4644—Cancer antigens
- A61K39/46448—Cancer antigens from embryonic or fetal origin
- A61K39/464482—Carcinoembryonic antigen [CEA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/7051—T-cell receptor (TcR)-CD3 complex
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0636—T lymphocytes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
- A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterized by the route of administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
- A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
- A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the cancer treated
- A61K2239/50—Colon
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2510/00—Genetically modified cells
Abstract
Se describen en la presente composiciones y métodos para el tratamiento de las metástasis hepáticas en un sujeto. Los métodos incluyen infusión arterial hepática (HAI) de linfocitos T modificados con el receptor de antígeno quimérico (CAR-T) que son altamente específicos para los antígenos tumorales tales como el antígeno carcinoembrionario (CEA). El método de HAI está optimizado para maximizar la exposición de las células modificadas a las células metastásicas, minimizando a su vez la exposición a las células sanas. Los métodos incluyen la coadministración de un segundo agente terapéutico, tal como IL-2.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201562147793P | 2015-04-15 | 2015-04-15 | |
PCT/US2016/027582 WO2016168493A1 (en) | 2015-04-15 | 2016-04-14 | Hepatic arterial infusion of car-t cells |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2017013247A true MX2017013247A (es) | 2018-08-15 |
Family
ID=57126310
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2017013247A MX2017013247A (es) | 2015-04-15 | 2016-04-14 | Infusion arterial hepatica de linfocitos t car. |
Country Status (13)
Country | Link |
---|---|
US (2) | US10471098B2 (es) |
EP (1) | EP3283083A4 (es) |
JP (1) | JP2018513216A (es) |
KR (1) | KR20180021364A (es) |
CN (1) | CN108135937A (es) |
AR (1) | AR104296A1 (es) |
AU (1) | AU2016248090A1 (es) |
CA (1) | CA2982603A1 (es) |
HK (1) | HK1251179A1 (es) |
IL (1) | IL255005A0 (es) |
MX (1) | MX2017013247A (es) |
TW (1) | TWI719019B (es) |
WO (1) | WO2016168493A1 (es) |
Families Citing this family (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP4230262A3 (en) | 2015-06-24 | 2023-11-22 | The Regents Of The University Of Michigan | Histotripsy therapy systems for the treatment of brain tissue |
CN107056952A (zh) * | 2017-05-10 | 2017-08-18 | 常州市第人民医院 | Cea.car‑t及其制备与应用 |
WO2019030757A1 (en) * | 2017-08-09 | 2019-02-14 | Ctg Pharma Ltd. | CHIMERIC ANTIGEN RECEPTOR FOR HER2 / NEU AND LYMPHOCYTES T THE EXPRESSANT |
JP2021501587A (ja) * | 2017-11-03 | 2021-01-21 | ソレント・セラピューティクス・インコーポレイテッドSorrento Therapeutics, Inc. | Cd38指向性キメラ抗原受容体構築物 |
WO2019108135A1 (en) | 2017-11-30 | 2019-06-06 | Singapore Health Services Pte. Ltd. | A system and method for classifying cancer patients into appropriate cancer treatment groups and compounds for treating the patient |
SG11202008568WA (en) * | 2018-03-09 | 2020-10-29 | Sorrento Therapeutics Inc | Dimeric antigen receptors (dar) |
CA3107383A1 (en) * | 2018-07-23 | 2020-01-30 | Magenta Therapeutics, Inc. | Use of anti-cd5 antibody drug conjugate (adc) in allogeneic cell therapy |
SG11202101014XA (en) * | 2018-08-02 | 2021-02-25 | Kite Pharma Inc | Chimeric antigen receptor therapy t cell expansion kinetics and uses thereof |
CN112384231A (zh) * | 2018-08-26 | 2021-02-19 | 奥伊斯细胞生物技术公司 | 用于治疗胶质母细胞瘤的方法 |
WO2020113083A1 (en) | 2018-11-28 | 2020-06-04 | Histosonics, Inc. | Histotripsy systems and methods |
EP3799881A1 (en) | 2019-10-04 | 2021-04-07 | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. | Single domain antibodies specifically binding globo - series glycans |
JPWO2021106832A1 (es) * | 2019-11-25 | 2021-06-03 | ||
CA3169465A1 (en) * | 2020-01-28 | 2021-08-05 | The Regents Of The University Of Michigan | Systems and methods for histotripsy immunosensitization |
WO2022066670A1 (en) * | 2020-09-22 | 2022-03-31 | Surefire Medical, Inc. D.B.A. Trisalus Life Sciences | Cancer therapy using toll-like receptor agonists |
US11883432B2 (en) | 2020-12-18 | 2024-01-30 | Century Therapeutics, Inc. | Chimeric antigen receptor system with adaptable receptor specificity |
WO2022173772A1 (en) * | 2021-02-09 | 2022-08-18 | Obi Pharma, Inc. | Globo series antigens-binding chimeric antigen receptors and uses thereof |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20020165360A1 (en) * | 2000-11-30 | 2002-11-07 | Junghans Richard P. | Chimeric effector cell receptors against carcinoembryonic antigen |
EP2389443B1 (en) * | 2009-01-23 | 2018-11-14 | Roger Williams Hospital | Retroviral vectors encoding multiple highly homologous non-viral polypeptides and the use of same |
KR101976882B1 (ko) * | 2011-03-23 | 2019-05-09 | 프레드 헛친슨 켄서 리서치 센터 | 세포 면역요법용 방법 및 조성물 |
CN103483452B (zh) * | 2012-06-12 | 2021-08-13 | 上海细胞治疗集团有限公司 | 双信号独立的嵌合抗原受体及其用途 |
KR102198058B1 (ko) * | 2012-10-02 | 2021-01-06 | 메모리얼 슬로안 케터링 캔서 센터 | 면역치료용 조성물 및 방법 |
IL298125A (en) | 2013-02-26 | 2023-01-01 | Memorial Sloan Kettering Cancer Center | Preparations and methods for immunotherapy |
-
2016
- 2016-04-14 JP JP2018505578A patent/JP2018513216A/ja active Pending
- 2016-04-14 AU AU2016248090A patent/AU2016248090A1/en not_active Abandoned
- 2016-04-14 CA CA2982603A patent/CA2982603A1/en not_active Abandoned
- 2016-04-14 TW TW105111666A patent/TWI719019B/zh not_active IP Right Cessation
- 2016-04-14 CN CN201680035380.XA patent/CN108135937A/zh active Pending
- 2016-04-14 KR KR1020177033070A patent/KR20180021364A/ko unknown
- 2016-04-14 WO PCT/US2016/027582 patent/WO2016168493A1/en active Application Filing
- 2016-04-14 MX MX2017013247A patent/MX2017013247A/es unknown
- 2016-04-14 EP EP16780765.0A patent/EP3283083A4/en not_active Withdrawn
- 2016-04-14 US US15/099,370 patent/US10471098B2/en not_active Expired - Fee Related
- 2016-04-15 AR ARP160101045A patent/AR104296A1/es unknown
-
2017
- 2017-10-15 IL IL255005A patent/IL255005A0/en unknown
-
2018
- 2018-08-21 HK HK18110746.6A patent/HK1251179A1/zh unknown
-
2019
- 2019-10-09 US US16/597,798 patent/US20200138863A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
US10471098B2 (en) | 2019-11-12 |
AR104296A1 (es) | 2017-07-12 |
KR20180021364A (ko) | 2018-03-02 |
EP3283083A4 (en) | 2018-10-31 |
HK1251179A1 (zh) | 2019-01-25 |
IL255005A0 (en) | 2017-12-31 |
CA2982603A1 (en) | 2016-10-20 |
US20200138863A1 (en) | 2020-05-07 |
AU2016248090A1 (en) | 2017-11-02 |
US20160303166A1 (en) | 2016-10-20 |
EP3283083A1 (en) | 2018-02-21 |
CN108135937A (zh) | 2018-06-08 |
JP2018513216A (ja) | 2018-05-24 |
WO2016168493A1 (en) | 2016-10-20 |
TW201708542A (zh) | 2017-03-01 |
TWI719019B (zh) | 2021-02-21 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX2017013247A (es) | Infusion arterial hepatica de linfocitos t car. | |
MX2019008208A (es) | Métodos para tratar el cáncer con anticuerpos anti-tim-3. | |
AU2020267226B2 (en) | Multispecific binding proteins targeting nkg2d, cd16. and trop2 | |
MX2020012573A (es) | Receptores del antigeno quimerico dirigidos al antigeno de maduracion de celulas b. | |
MX2019005465A (es) | Metodo de tratamiento de un tumor inmunoterapeutico. | |
MX2022001222A (es) | Anticuerpos anti proteina inmunoglobulina de linfocitos t y dominio de mucina 3 (tim-3) y metodos para usarlos. | |
PH12020551160A1 (en) | Chimeric antigen receptors targeting cd70 | |
MX2023007045A (es) | Anticuerpos anti antigeno 4 del linfocito t citotoxico (ctla-4) y metodos de uso de los mismos. | |
PH12019500193A1 (en) | Chimeric antigen receptors targeting bcma and methods of use thereof | |
MX2023000818A (es) | Anticuerpos anti-antigeno 4 del linfocito t citotoxico (ctla-4) y metodos para uso de los mismos. | |
MY181834A (en) | Treatment of cancer using humanized anti-bcma chimeric antigen receptor | |
HK1247212A1 (zh) | 針對腫瘤抗原ny-eso-1的mhc i和mhc ii-限制表位的癌症的組合t細胞受體基因療法 | |
MX2018010473A (es) | Terapia de combinacion con anticuerpos anti cumulo de diferenciacion 73 (cd73). | |
MX2019008207A (es) | Métodos para tratar el cáncer con anticuerpos anti-pd-1. | |
MX2017004526A (es) | Terapia combinada de anticuerpos biespecificos especificos para fap y dr5 y agentes quimioterapeuticos. | |
MX2017005976A (es) | Moleculas de union especificas para grupo de diferenciacion 73 (cd73) y usos de las mismas. | |
MX2017001013A (es) | Tratamiento de cáncer usando un receptor quimérico de antígeno cll-1. | |
MY189028A (en) | Anti-cd123 chimeric antigen receptor (car) for use in cancer treatment | |
NZ732211A (en) | Combination immunotherapy approach for treatment of cancer | |
MX2021002970A (es) | Proteinas de union a nkg2d, cd16 y un antigeno asociado a tumor. | |
PH12016501976A1 (en) | Antibodies, pharmaceutical compositions and uses thereof | |
GB2567362A (en) | HDAC inhibitors for use with NK cell based therapies | |
EA201692100A1 (ru) | Новые антитела против rnf43 и способы их применения | |
EP3463450A4 (en) | COMPOSITIONS AND METHODS FOR TUMOR VACCINATION WITH PROSTATE CANCER-ASSOCIATED ANTIGENS | |
MX2018005825A (es) | Celulas inmunes modificadas y usos de las mismas. |